Wuhan Keqian Biology Co (SHSE:688526) EBIT : ¥348.8 Mil (TTM As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Wuhan Keqian Biology Co EBIT?

Wuhan Keqian Biology Co's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was ¥125.1 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was ¥348.8 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Wuhan Keqian Biology Co's annualized ROC % for the quarter that ended in Sep. 2024 was 11.64%. Wuhan Keqian Biology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 29.22%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Wuhan Keqian Biology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 6.89%.

Wuhan Keqian Biology Co EBIT Historical Data

The historical data trend for Wuhan Keqian Biology Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan Keqian Biology Co EBIT Chart

Wuhan Keqian Biology Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

253.08

520.09

661.86

472.05

465.74

Wuhan Keqian Biology Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT	Get a 7-Day Free Trial															138.92	47.45	102.02	74.26	125.09

Competitive Comparison of Wuhan Keqian Biology Co's EBIT

For the Biotechnology subindustry, Wuhan Keqian Biology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Wuhan Keqian Biology Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Wuhan Keqian Biology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Wuhan Keqian Biology Co's EV-to-EBIT falls into.

Wuhan Keqian Biology Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥348.8 Mil.

Wuhan Keqian Biology Co (SHSE:688526) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Wuhan Keqian Biology Co's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

	ROC % (Q: Sep. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2024 )	+	Invested Capital (Q: Sep. 2024 ))	/ count )
=	404.188 * ( 1 - 13.01% )	/	( (2923.155	+	3120.108)	/ 2 )
=	351.6031412	/	3021.6315
=	11.64 %

where

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	4470.856	-	213.43	-	( 1334.271	-	max(0, 620.43	-	2571.347	+	1334.271	))
=	2923.155

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	4431.965	-	246.06	-	( 1065.797	-	max(0, 485.28	-	2396.57	+	1065.797	))
=	3120.108

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Wuhan Keqian Biology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2024		Q: Sep. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	500.356	/	( ( (836.685 + max(839.81, 0))	+	(849.792 + max(898.948, 0)) )	/	2 )
=	500.356	/	( ( 1676.495	+	1748.74 )	/	2 )
=	500.356	/	1712.6175
=	29.22 %

where Working Capital is:

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(297.759	+	133.64	+	795.498)	-	(213.43	+	0	+	173.657)
=	839.81

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(334.409	+	110.569	+	880.971)	-	(246.06	+	0	+	180.941)
=	898.948

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Wuhan Keqian Biology Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2024 )
	=	348.819	/	5059.026
	=	6.89 %

Wuhan Keqian Biology Co EBIT Related Terms

Thank you for viewing the detailed overview of Wuhan Keqian Biology Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Wuhan Keqian Biology Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Wuhan Keqian Biology Co Ltd (SHSE:688526) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 419, Gaoxin 2nd Road, Donghu New Technology Development Zone, Hubei Province, Wuhan, CHN, 430073

Website

http://www.kqbio.com

Wuhan Keqian Biology Co Ltd is engaged in research and development, production, sales and animal epidemic prevention technical services of veterinary biological products. The company's products include Combination plan; Vaccine for swine; Poultry vaccine; Pet vaccine; and Diagnostic reagent.

Executives

Ye Zhang Fa	Supervisors
Hao Gen Xi	Core technical personnel
Zhang Hua Wei	Core technical personnel
Zhou Ming Guang	Core technical personnel
Zou Tian Tian	senior management
Xu Gao Yuan	Director
Chen Guan Ping	Director

Wuhan Keqian Biology Co Headlines

No Headlines